GLP-1 Drugs for Obesity: Current Landscape, Challenges, and What Comes Next
Comprehensive review of GLP-1 obesity therapeutics covers current drugs (semaglutide, liraglutide, tirzepatide), emerging agents, weight regain challenges, cost barriers, and counterfeit drug risks.
Quick Facts
What This Study Found
GLP-1 drugs are highly effective for obesity but face challenges including weight regain on discontinuation, cost barriers, GI side effects, and counterfeit drug risks.
Key Numbers
Three FDA-approved GLP-1 drugs for obesity: liraglutide, semaglutide, and tirzepatide. Additional agents are used off-label.
How They Did This
Comprehensive review of GLP-1 RA obesity treatment evidence, emerging agents, and current obstacles to widespread implementation.
Why This Research Matters
GLP-1 drugs could help the 650+ million people with obesity worldwide, but only if the barriers of cost, access, tolerability, and long-term treatment sustainability are addressed.
The Bigger Picture
We are at an inflection point in obesity medicine. GLP-1 drugs work, but making them accessible, affordable, and sustainable for the hundreds of millions who need them is the next great challenge. This review maps both the promise and the obstacles.
What This Study Doesn't Tell Us
Review reflects a rapidly evolving landscape — new drugs and pricing changes may alter conclusions. Different healthcare systems face different access challenges. Long-term safety data continues to accumulate.
Questions This Raises
- ?Will generic or biosimilar GLP-1 drugs solve the cost barrier?
- ?Can combination strategies reduce weight regain when stopping GLP-1 drugs?
- ?How can healthcare systems address counterfeit GLP-1 drug risks?
Trust & Context
- Key Stat:
- Promise vs barriers GLP-1 drugs achieve 15-17% weight loss but face cost, regain, tolerability, and counterfeit challenges limiting their impact
- Evidence Grade:
- Strong evidence: comprehensive review of a well-established drug class with extensive clinical trial and real-world data.
- Study Age:
- Published in 2025. Captures the most current GLP-1 obesity treatment landscape.
- Original Title:
- Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon.
- Published In:
- Journal of obesity, 2025, 9919810 (2025)
- Authors:
- Abdelrahman, Riad Mohammed, Musa, Taha Hussein, Arbab, Ismail Adam, Suliman, Mohsen Hussein, Ahmed, Eltieb Omer, Mohamed, Asma Noureldaim, Musa, Hassan Hussein, Jalal, Mohammed, Gasmallah, Sahar Ibrahim
- Database ID:
- RPEP-09738
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What happens when you stop GLP-1 drugs?
Most patients regain significant weight after stopping GLP-1 drugs — typically about two-thirds of lost weight within a year. This means obesity treatment with GLP-1 drugs may need to be long-term, similar to blood pressure or cholesterol medications.
Why are GLP-1 drugs so expensive?
At ,000+ per month without insurance, cost is the biggest barrier to GLP-1 drug access. Pharmaceutical pricing, limited competition, and high demand contribute. Biosimilar versions and competition from new agents may eventually reduce prices.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09738APA
Abdelrahman, Riad Mohammed; Musa, Taha Hussein; Arbab, Ismail Adam; Suliman, Mohsen Hussein; Ahmed, Eltieb Omer; Mohamed, Asma Noureldaim; Musa, Hassan Hussein; Jalal, Mohammed; Gasmallah, Sahar Ibrahim. (2025). Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon.. Journal of obesity, 2025, 9919810. https://doi.org/10.1155/jobe/9919810
MLA
Abdelrahman, Riad Mohammed, et al. "Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon.." Journal of obesity, 2025. https://doi.org/10.1155/jobe/9919810
RethinkPeptides
RethinkPeptides Research Database. "Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Pr..." RPEP-09738. Retrieved from https://rethinkpeptides.com/research/abdelrahman-2025-harnessing-glp1-receptor-agonists
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.